Genflow Biosciences PLC Announces Update, Equity Issue and PDMR Notification
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced on 9 October 2025 that it has terminated the previously announced subscription from 2 October 2025 and completed an Alternative Transaction raising gross proceeds of £440,000 via an allotment of 40,000,000 new ordinary shares at 1.1 pence per share. The shares were allotted to CEO Eric Leire, who will direct 35,454,546 shares to a consortium of existing shareholders and retain 4,545,454 shares.
Concurrent warrants will be issued one-for-one, exercisable at 1.2 pence for 24 months. Admission of the new shares is expected on or around 16 October 2025, after which total issued share capital and voting rights will be 493,547,942. The allotment used an employee-offer prospectus exemption under the UK Prospectus Regulation.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) ha annunciato il 9 ottobre 2025 di aver terminato la precedentemente annunciata sottoscrizione del 2 ottobre 2025 e completato un Alternative Transaction che ha raccolto proventi lorde di £440.000 tramite l’assegnazione di 40.000.000 nuove azioni ordinarie a 1,1 pence per azione. Le azioni sono state assegnate al CEO Eric Leire, che finirà per destinare 35.454.546 azioni a un consorzio di azionisti esistenti e manterrà 4.545.454 azioni.
Saranno emessi warrant contestualmente in rapporto uno a uno, esercitabili a 1,2 pence per 24 mesi. L’ammissione delle nuove azioni è prevista all’incirca per 16 ottobre 2025, dopo il quale il capitale sociale emesso totale e i diritti di voto ammontano a 493.547.942. L’assegnazione ha fatto uso di un’esenzione dal prospetto per offerta ai dipendenti ai sensi del Regolamento sui prospetti del Regno Unito.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) anunció el 9 de octubre de 2025 que ha terminado la suscripción anunciada previamente del 2 de octubre de 2025 y completado una Transacción Alternativa que ha logrado unos ingresos brutos de £440.000 mediante la asignación de 40.000.000 nuevas acciones ordinarias a un precio de 1,1 peniques por acción. Las acciones fueron asignadas al CEO Eric Leire, quien destinará 35.454.546 acciones a un consorcio de accionistas existentes y retendrá 4.545.454 acciones.
Se emitirán warrants concurrentes uno a uno, exercitables a 1,2 peniques durante 24 meses. Se espera la admisión de las nuevas acciones alrededor del 16 de octubre de 2025, tras lo cual el capital social total en circulación y los derechos de voto serán de 493.547.942. La asignación utilizó una exención de folleto por oferta de empleados conforme al Reglamento de Folletos del Reino Unido.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF)은 2025년 10월 9일에 2025년 10월 2일에 발표된 기존의 구독을 종료했고, Alternative Transaction을 완료하여 총수입 £440.000를 40,000,000주의 신규 보통주를 주당 1.1펜스에 할당해 조달했다고 발표했습니다. 주식은 CEO Eric Leire에게 배정되었으며, 그는 35,454,546주를 기존 주주 연합에 위임하고 4,545,454주를 보유합니다.
동시에 1대1 비율의 워런트가 발행되며 행사가는 1.2펜스, 기간은 24개월입니다. 신규 주식의 상장은 2025년 10월 16일경으로 예상되며, 이후 총 발행 주식 수와 의결권은 493,547,942가 될 것입니다. 할당은 영국 증권규정의 직원오퍼 공모 예외를 사용했습니다.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) a annoncé le 9 octobre 2025 avoir résilié la souscription précédemment annoncée du 2 octobre 2025 et avoir conclu une Transaction Alternative ayant levé des fonds bruts de £440 000 via une allocation de 40 000 000 nouvelles actions ordinaires à 1,1 pence par action. Les actions ont été attribuées au PDG Eric Leire, qui demandra 35 454 546 actions à un consortium d’actionnaires existants et conservera 4 545 454 actions.
Des warrants seront émis en parallèle, à raison d’un pour un, exercables à 1,2 pence pendant 24 mois. L’admission des nouvelles actions est prévue autour du 16 octobre 2025, après quoi le capital social total en circulation et les droits de vote seront de 493 547 942. Cette attribution a utilisé une exemption de prospectus pour les offres aux employés en vertu du Règlement britannique sur les prospectus.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) gab am 9. Oktober 2025 bekannt, dass es die zuvor am 2. Oktober 2025 angekündigte Zeichnung beendet hat und eine Alternative Transaktion abgeschlossen wurde, die Bruttoerlöse von £440.000 durch eine Allokation von 40.000.000 neuen Stammaktien zu 1,1 Pence pro Aktie erzielte. Die Aktien wurden dem CEO Eric Leire zugewiesen, der 35.454.546 Aktien an ein Konsortium bestehender Aktionäre übertragen wird und 4.545.454 Aktien behält.
Zeitgleich werden Inhaber-Warrants im Verhältnis 1:1 ausgegeben, mit Ausübungspreis von 1,2 Pence für 24 Monate. Die Aufnahme der neuen Aktien wird voraussichtlich um den 16. Oktober 2025 erfolgen, danach wird das insgesamt ausgegebene Kapital und die Stimmrechte 493.547.942 betragen. Die Zuteilung erfolgte unter Ausnutzung einer Arbeitnehmerangebotserlaubnis gemäß der UK Prospectus Regulation.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) أعلنت في 9 أكتوبر 2025 أنها أنهت الاشتراك الذي أعلن عنه سابقاً في 2 أكتوبر 2025 واكملت صفقة بديلة حققت عائداً إجمالياً قدره £440,000 من خلال تخصيص 40,000,000 سهماً ع cours جديدة بسعر 1.1 بنساً للسهم الواحد. الأسهم قد تم تخصيصها للرئيس التنفيذي إريك ليير، الذي سيوجه 35,454,546 سهماً إلى اتحاد المساهمين الحاليين وسيحتفظ بـ 4,545,454 سهماً.
سيتم إصدار حقوق ووَرات مرتبطة بنفس النسبة 1 مقابل 1، قابلة للممارسة بسعر 1.2 بنس لمدة 24 شهراً. من المتوقع أن يتم الإدراج للأسهم الجديدة حوالي 16 أكتوبر 2025، بعد ذلك ستبلغ إجمالى رأس المال المصدَر وحقوق التصويت 493,547,942. استخدمت التخصيص استثناء عرض الموظفين بموجب تنظيم المملكة المتحدة الخاص بالعرض.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) 于 2025年10月9日 宣布，已终止原先于 2025年10月2日 公布的认购，并完成了一项 另类交易，通过以每股 1.1便士 的价格配发 40,000,000股新普通股，募集毛额 £440,000。股票已分配给 CEO Eric Leire，他将把 35,454,546股转给现有股东联盟，并保留 4,545,454股。
同时发行1对1的权证，可在 24个月内按 1.2便士 行使。新股的上市预计在大约 2025年10月16日，此后总发行股本及表决权将为 493,547,942。此次配发利用了英国《招股说明书条例》下的员工要约豁免。
- Gross proceeds raised: £440,000
- New shares to rank pari passu and expected Admission on 16 Oct 2025
- Warrants issued one-for-one exercisable at 1.2p for 24 months
- Post-issue dilution: 40,000,000 new shares represent ≈8.1% of post-issue shares
- Potential further dilution if warrants are exercised at 1.2p within 24 months
- Subscription routed via CEO using employee-offer exemption, raising governance and related-party scrutiny
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Termination of Initial Transaction, Subscription of New Ordinary Shares, Warrant Issue and PDMR Dealings
LONDON, UK, AL / ACCESS Newswire / October 9, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), announces that its board of directors has taken the decision to terminate, and not to proceed with, the subscription announced by the Company on 2 October 2025 (the "Initial Transaction"). Please see Issue of Equity - Correction - 12:37:10 02 Oct 2025 - GENF News article | London Stock Exchange.
In the alternative, it has raised gross proceeds of
The Board has taken this decision on the basis that the Alternative Transaction is more favourable to, and less dilutive for, shareholders than the Initial Transaction.
Issuance of the New Ordinary Shares
The Company continues to be unable to issue and admit the New Ordinary Shares without either the publication of a prospectus approved by the Financial Conduct Authority ("FCA") or relying upon an exemption to the requirement to issue a prospectus.
Consequentially, the Alternative Transaction involves a subscription by Eric Leire, CEO and director of the Company, for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article 1(4)(i) and 1(5) (h) of the UK Prospectus Regulation.
Following allotment of the New Ordinary Shares, Eric Leire has agreed to direct the issue of 35,454,546 of such New Ordinary Shares to a consortium of existing shareholders (the "Purchasers"). Eric Leire will be issued the remaining 4,545,454 New Ordinary Shares.
Warrants
Concurrent with the purchase of the New Ordinary Shares, the Purchasers and Eric Leire will receive warrants from the Company on a one-for-one basis. These warrants will be exercisable for a period of 24 months at an exercise price of 1.2 pence ("Exercise Price"), subject to adjustment in certain circumstances as set out in the warrant instrument.
Total Voting Rights
Application will be made for the 40,000,000 New Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 16 October 2025 (the "Admission").
Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 493,547,942.
The above figure of 493,547,942 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Dr. Eric Leire, CEO of Genflow, commented: "We would like to express our sincere gratitude to our historical shareholders for their continued confidence and commitment to Genflow's vision. Their ongoing support reflects a shared belief in our mission. With this additional capital, Genflow is able to deliver on our near-term objectives."
UK Market Abuse Regulation (UK MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Genflow Biosciences is Eric Leire, Chief Executive Officer.
Notification of transactions of directors, persons discharging managerial responsibilities or connected persons
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||||
a) | Name | Eric Leire | ||||||||
2. | Reason for the Notification | |||||||||
a) | Position/status | PDMR | ||||||||
b) | Initial notification / Amendment | Initial notification | ||||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | Genflow Biosciences plc | ||||||||
b) | LEI | 213800HVOFXRXVEGDN62 | ||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of | ||||||||
Identification Code | GB00BP2C3V08 | |||||||||
b) | Nature of the transaction | Off Market Allotment and Subscription | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information: Aggregated volume Price | 40,000,000 Ordinary Shares 1.1 pence per Ordinary Share | ||||||||
e) | Dates of the transaction | 8 October 2025 | ||||||||
f) | Place of the transactions | London | ||||||||
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
DISCLAIMER
The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.
This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.
Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
How much did Genflow (GENFF) raise in the 9 October 2025 equity issue?
What dilution does the Genflow (GENFF) share issue cause after Admission on 16 October 2025?
Who subscribed for the new Genflow (GENFF) shares and how were they allocated?
What warrants were issued alongside the Genflow (GENFF) share allotment?
When will the new Genflow (GENFF) shares be admitted to trading?
Why did Genflow (GENFF) use a prospectus exemption for the 9 October 2025 transaction?
